Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (3376)	4/16/1998 1:58:00 PM
From: Dauntless	Read Replies (1) \| Respond to of 7041

Linda, but I do know I've been through acquisitions in the medical industry - from both sides & I know how much detail they get into. A big pharma company may "gamble" early on in the development of a new compound - that's become very popular in recent years as the total cost of developing & testing new drugs has skyrocketed. But the amount of uncertainty is MUCH lower for a drug that's been through phase III trials - why should they gamble then? The only "gamble" at that time is whether it will get approved in the particular segment it's intended for - and they have a pretty good handle on that. Several shorts on this thread have offered examples of partnership deals that have failed - but every one was begun with compounds at a much earlier stage of testing. Another indication of their confidence is that they are preparing the NDA - a MONSTROUS task. The submission for TXB's anticoagulant was nearly 300 3" looseleaf notebooks - probably several man-years go into these filings - why bother, unless you're very confident (or it's your only chance for glory, which doesn't apply to SGP) <<<In the case of Vasomax a lot of physicians are saying it doesn't work and a lot of people who have reviewed the available info on the trials see indications it doesn't work.>>> I don't agree. First of all, what do you call "a lot"? The serious critics on this thread could probably be counted on one hand - and we don't know if they are being totally objective - Tuna & Bradpalm had obvious biases. Are you hearing this from personal acquaintances, not on this thread? Second, how much information have been able to review? Zonagen/SGP, like EVERY other reputable company in this situation, have not released much information at all. We will have to wait until the filing or the AUA meeting before the average MD will have access to as much information as the decisionmakers at SGP did BEFORE they plunked down their nickel. And I guarantee you that many more qualified people reviewed that information than have commented on this thread about what's been released to date.. I'm not familiar with LIPO or when you got in - can you educate me vis-a-vis my points above? Thanks for listening